Compare GSK plc (GSK) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs State Street Technology Select Sector SPDR ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while State Street Technology Select Sector SPDR ETF trades at $198.78 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| GSK | XLK | |
|---|---|---|
Market Cap | $91.88B | $132.55B |
Volume | 7,730,529 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $202.00 |
52-Week Low | $43.24 | $127.49 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
XLK, the Technology Select Sector SPDR ETF, trades at $198.78, down 1.3% over the past day amid broader tech sector pressure. The technical outlook remains bullish based on moving averages, with neutral oscillators suggesting consolidation near the pivot point of $199. Recent news highlights AI-driven momentum in software stocks and ETF concentration concerns, while a future dividend of $0.22 is scheduled for September 2026.
The ETF's outlook is supported by strong AI investment themes and large-cap tech earnings resilience, but risks include interest rate sensitivity and high concentration in semiconductor holdings. Analyst sentiment is mixed, with some favoring alternative tech ETFs for better diversification. Key resistance lies at $201, with support at $196.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
